Literature DB >> 18435951

Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database).

Nancy M Albert1, Kimberly K Birtcher, Christopher P Cannon, David C Goff, Jyotsna Mulgund, Li Liang, Gregg C Fonarow.   

Abstract

Lipid-lowering therapy prevents morbidity and mortality in patients with coronary artery disease (CAD), but little is known regarding ordering practices in patients hospitalized with CAD events. Patients at participating hospitals of Get with The Guidelines-CAD, a hospital performance improvement program, were entered into a registry. Factors associated with discharge lipid-lowering therapy prescription were identified and the effect of in-hospital low-density lipoprotein cholesterol measurement on therapy prescription was evaluated. A total of 98,880 patients were enrolled at 405 hospitals. At discharge, lipid-lowering therapy was prescribed in 84.7% of patients and was associated with percutaneous coronary intervention and angiotensin-converting enzyme inhibitor, aspirin, and beta-blocker therapies at discharge, but not cardiac rehabilitation referral or coronary artery bypass grafting (all p<0.0001). After adjustment for patient characteristics, men were more likely (odds ratio [OR] 1.23, 95% confidence interval [CI] 1.18 to 1.29; p<0.0001) and patients with heart failure were less likely to be prescribed lipid-lowering therapy (OR 0.64, 95% CI 0.59 to 0.69, p<0.0001). Patients who had low-density lipoprotein cholesterol measured during hospitalization were more likely to be prescribed lipid-lowering therapy (OR 1.56, 95% CI 1.48 to 1.65, p<0.0001). Lipid-lowering therapy prescription was associated positively with higher body mass index, history of dyslipidemia, and previous myocardial infarction and negatively with history of renal insufficiency, stroke, and hypertension. In conclusion, despite consistent benefits of lipid-lowering therapy in patients hospitalized for CAD events, discharge prescription varied by patient characteristics, in-hospital assessment, and treatment decisions. Additional efforts are needed to improve evidence-based lipid-lowering therapy prescription for eligible patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18435951     DOI: 10.1016/j.amjcard.2007.12.020

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Another treatment gap: restarting secondary prevention medications: the Women's Health Initiative.

Authors:  Jennifer G Robinson; Robert Wallace; Monika M Safford; Mary Pettinger; Barbara Cochrane; Marcia G Ko; Mary Jo O'Sullivan; Kamal Masaki; Helen Petrovich
Journal:  J Clin Lipidol       Date:  2010 Jan-Feb       Impact factor: 4.766

2.  Effect of Financial Incentives to Physicians, Patients, or Both on Lipid Levels: A Randomized Clinical Trial.

Authors:  David A Asch; Andrea B Troxel; Walter F Stewart; Thomas D Sequist; James B Jones; AnneMarie G Hirsch; Karen Hoffer; Jingsan Zhu; Wenli Wang; Amanda Hodlofski; Antonette B Frasch; Mark G Weiner; Darra D Finnerty; Meredith B Rosenthal; Kelsey Gangemi; Kevin G Volpp
Journal:  JAMA       Date:  2015-11-10       Impact factor: 56.272

3.  Statin use following hospitalization among Medicare beneficiaries with a secondary discharge diagnosis of acute myocardial infarction.

Authors:  Huifeng Yun; Monika M Safford; Todd M Brown; Michael E Farkouh; Shia Kent; Pradeep Sharma; Meredith Kilgore; Vera Bittner; Robert S Rosenson; Elizabeth Delzell; Paul Muntner; Emily B Levitan
Journal:  J Am Heart Assoc       Date:  2015-02-09       Impact factor: 5.501

4.  Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.

Authors:  Alon Eisen; Christopher P Cannon; Eugene Braunwald; Dylan L Steen; Jing Zhou; Erica L Goodrich; KyungAh Im; Anthony J Dalby; Jindrich Spinar; Shruti Daga; Mary Ann Lukas; Michelle L O'Donoghue
Journal:  J Am Heart Assoc       Date:  2017-01-11       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.